Subscribe

Nanologica AB (publ) (NICA.ST)

SEK0.48 +0.01 (+1.05%)
SE STO Healthcare Medical - Pharmaceuticals
Address Forskargatan 20 G 151 36
Södertälje, AB, SE
CEO Andreas Bhagwani
Website nanologica.com
IPO 2015-10-30
ISIN SE0005454873

Explore sections of this company profile

Description

Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK0.48 +0.01 (+1.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
-0.07
Float Shares
50.61M
Free Float %
57.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+12.62% +60.88% -31.59% +84.60% -22.46% -2.40% -40.00% -93.55% -95.40% -96.55% -95.81%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.48
Ratings Trend (MoM)
Rating 2026-01 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-2.04
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +45.3% ★ Q1'26: +99.6% (vs Q1'25)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    +56.1% ★ Q1'26: +700.0% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    -186.5% Q1'26: -29.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    -222.4% Q1'26: -46.1% (vs Q1'25)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    -115.9% Q1'26: -22.3% (vs Q1'25)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +78.4% Q1'26: +2.6% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    -0.62× Q1'26: -6.93× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.12) × ERP
WACC = 75% × Ke + 25% × Kd (21.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.48
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
2.00M
est: 2.44M (-18.0%)
2.60M
est: 3.10M (-16.0%)
4.15M
est: 4.42M (-6.3%)
10.23M
est: 14.45M (-29.2%)
16.14M
est: 16.00M (+0.8%)
12.91M
est: 13.90M (-7.1%)
1.56M
est: 2.00M (-22.3%)
1.44M
est: 8.50M (-83.0%)
14.54M
est: 19.80M (-26.6%)
21.13M
est: 32.00M (-34.0%)
83.10M
83.10M – 83.10M
+159.7% YoY
124.00M
124.00M – 124.00M
+49.2% YoY
EBITDA
-18.55M
est: -2.35M (-690.4%)
-15.86M
est: -2.98M (-432.6%)
-18.87M
est: -4.25M (-343.5%)
-14.51M
est: -13.90M (-4.4%)
-13.05M
est: -15.39M (+15.2%)
-31.13M
est: -13.37M (-132.8%)
-38.36M
est: -1.92M (-1,894.3%)
-62.12M
est: -8.50M (-631.2%)
-45.17M
est: -19.80M (-128.1%)
-34.55M
est: -32.00M (-8.0%)
-83.10M
-83.10M – -83.10M
-159.7% YoY
-124.00M
-124.00M – -124.00M
-49.2% YoY
EBIT
-22.27M
est: -2.44M (-812.3%)
-19.19M
est: -3.10M (-520.0%)
-19.67M
est: -4.42M (-344.7%)
-19.96M
est: -14.45M (-38.1%)
-18.72M
est: -16.00M (-17.0%)
-41.60M
est: -13.90M (-199.2%)
-50.22M
est: -2.00M (-2,411.1%)
-69.45M
est: -8.50M (-717.5%)
-59.29M
est: -19.80M (-199.5%)
-46.99M
est: -32.00M (-46.9%)
-83.10M
-83.10M – -83.10M
-159.7% YoY
-124.00M
-124.00M – -124.00M
-49.2% YoY
Net Income
-22.46M
est: -229.84M (+90.2%)
-20.10M
est: -195.46M (+89.7%)
-20.89M
est: -55.50M (+62.4%)
-21.47M
est: -55.95M (+61.6%)
-24.83M
est: -37.88M (+34.5%)
-50.13M
est: -71.03M (+29.4%)
-55.09M
est: -70.08M (+21.4%)
-75.16M
-65.63M
est: -52.56M (-24.9%)
-51.29M
est: -35.04M (-46.4%)
94.17M
94.17M – 94.17M
+368.7% YoY
8.84M
8.84M – 8.84M
-90.6% YoY
SGA
10.53M
est: 5.26M (+100.1%)
11.23M
est: 6.68M (+68.2%)
8.24M
est: 9.54M (-13.7%)
10.75M
est: 31.17M (-65.5%)
11.51M
est: 34.50M (-66.6%)
12.58M
est: 29.97M (-58.0%)
14.14M
est: 4.31M (+227.9%)
—
est: 17.11M (-100.0%)
—
est: 39.87M (-100.0%)
—
est: 64.44M (-100.0%)
167.35M
167.35M – 167.35M
+159.7% YoY
249.71M
249.71M – 249.71M
+49.2% YoY
EPS
-6.18
est: -4.64 (-33.2%)
-4.35
est: -3.95 (-10.2%)
-1.26
est: -1.12 (-12.5%)
-1.27
est: -1.13 (-12.4%)
-1.03
est: -0.76 (-34.7%)
-1.77
est: -1.43 (-23.4%)
-1.81
est: -1.41 (-27.9%)
-2.05
-1.32
est: -0.59 (-121.9%)
-0.58
est: -0.40 (-46.3%)
1.07
1.07 – 1.07
+368.7% YoY
0.10
0.10 – 0.10
-90.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-21 A- 4/5 1/5 5/5 5/5 1/5 3/5 5/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-9.71M
OE per share TTM
-0.11
Owner's Yield
-14.64%
Maintenance CapEx ratio
25.78%
Maint CapEx / Avg PPE
157.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-24.7K
Shares Outstanding
88.73M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Andreas Bhagwani Chief Executive Officer 3M male
Annette Roos Chief Executive Officer of Syntagon AB — female
Eva Osterman Chief Financial Officer — female
Johanna Johansson Director of IR, Communications & Marketing — —
Katarina Alenas Senior Vice President of Chromatography — female
Åsa Bergström Chief Operating Officer — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals